Veerhealth Care share news, announcements and annual reports
BSE: 511523Pharmaceuticals & BiotechnologySmall Cap
Share price at the BSE close on 27 Oct 2026. Previous close ₹49.43.
27 Oct: open ₹49.40, high ₹49.70, low ₹48.31
- Market capMarket capitalisation. Share price times the number of shares: what the whole company is worth at the day's price. The rank is by average market value over the six months to Jun 2026, among listed companies. Market capitalisation: how it is worked out
- ₹98 Cr3,569th largest listed
- P/EPrice to earnings, trailing. Market cap divided by the profit of the last twelve months (the latest four quarters, or two half years for a company that reports half-yearly) that belongs to the company's own shareholders, after the share of the other owners of its subsidiaries: what investors pay for each rupee of a year's profit. Price to earnings, trailing: how it is worked out
- 64.26
- P/E without one-offsPrice to earnings without one-off items. Market cap divided by core profit: the profit of the last twelve months (the latest four quarters, or two half years for a company that reports half-yearly) that belongs to the company's own shareholders, less one-off items (exceptional items and the result of businesses sold or closed). Shown where the one-off items move that profit by more than a tenth. The last twelve months' profit includes −₹0.31 crore of one-off items, the largest of them in the quarter to Mar 2026.
- 53.44
- P/BPrice to book. Market cap divided by the net worth that belongs to the company's own shareholders, its assets less everything it owes and less the other owners' share of its subsidiaries, on its latest balance sheet. Price to book: how it is worked out
- 4.29
- Dividend yieldDividend yield. Dividends paid per share in the twelve months to the day, as a percentage of the day's share price.
- Nonein the last 12 months
- ROEReturn on equity. Profit over the last twelve months (the latest four quarters, or two half years for a company that reports half-yearly) that belongs to the company's own shareholders, as a percentage of their net worth, the money they have in the business. Net worth is the average of the latest balance sheet and the one a year before it.
- 6.8%
- ROE without one-offsReturn on equity without one-off items. Core profit, the profit of the last twelve months (the latest four quarters, or two half years for a company that reports half-yearly) that belongs to the company's own shareholders less one-off items (exceptional items and the result of businesses sold or closed), as a percentage of the same net worth as the return on equity. Shown where the one-off items move that profit by more than a tenth. The last twelve months' profit includes −₹0.31 crore of one-off items, the largest of them in the quarter to Mar 2026.
- 8.2%
- ROCEReturn on capital employed. Operating profit after depreciation (revenue less operating expenses and depreciation, without other income and one-off items) as a percentage of all the money the business runs on: the whole group's net worth, the other owners of its subsidiaries included, plus borrowings. Lease liabilities are not counted: the results filings do not state them. The profit is over the last twelve months (the latest four quarters, or two half years for a company that reports half-yearly); net worth and borrowings are on the latest balance sheet.
- 11.0%
- Debt to equityDebt to equity. Borrowings divided by the whole group's net worth, the other owners of its subsidiaries included: rupees borrowed for each rupee of equity in the business. Lease liabilities are not counted: the results filings do not state them. From the balance sheet at the end of Mar 2026.
- 0.20
- Volume, BSEVolume. Shares traded on the last trading day. Volume in the glossary
- 89,256
Veerhealth Care share news and announcements
543 announcements, routine notices left out, newest first. Page 3 of 11.
May 2025
30 May · Board meeting
21 May · Board meeting
Meeting on 30 May 2025: audited results and final dividend16 May · Announcement Under Regulation 30 (LODR) - Successful Closure Of USFDA Inspection Under 21 CFR 20.64(D)(3)
Apr 2025
4 Apr · Compliances-Compliance Certificate For The Period Ended March 31, 2025
Mar 2025
Feb 2025
4 Feb · Board meeting
Meeting on 12 Feb 2025: quarterly results
Dec 2024
20 Dec · Analysts
18 Dec · Announcement Under Regulation 30 (LODR) - Introduction Of New Division In Hospital Care Segment
14 Dec · Analysts
11 Dec · Announcement Under Regulation 30 (LODR) - Closure Of Assessment By USFDA Of Form 4003 - FDA Pre-Inspection Records Request
Nov 2024
26 Nov · Board meeting
Meeting on 26 Nov 2024: rights issue26 Nov · Board meeting
6 Nov · Board meeting
Meeting on 14 Nov 2024: quarterly results
Oct 2024
Sep 2024
12 Sep · Business
Aug 2024
14 Aug · Board meeting
6 Aug · Announcement Under Regulation 30 (LODR) - Facility Expansion And New Production Capabilities
6 Aug · Board meeting
Meeting on 14 Aug 2024: increase in authorised capital and quarterly results
Jul 2024
22 Jul · Business
11 Jul · Business
Jun 2024
14 Jun · 'Ayuveer' Products Now Available On Nykaa For Purchase
May 2024
30 May · Board meeting